Multilevel Interventions to Increase Adherence to Lung Cancer Screening

Lung Cancer Clinical Trial

— Larch  

Official title:

Multilevel Interventions to Increase Adherence to Lung Cancer Screening

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05747443
• Other study ID #: 220-115.001
• Status: Enrolling by invitation
• Phase: N/A
• Start date: December 12, 2022
• Est. completion date: June 30, 2026

Study information

• Verified date: March 2023
• Source: Kaiser Permanente
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Screening for lung cancer has the potential for a profound public health benefit. Repeat annual screening is necessary for early detection of lung cancer. The investigators will test two interventions which include patient education and reminders to improve adherence to lung cancer screening.

Description:

Screening for lung cancer has the potential for a profound public health benefit.

Successful population-based screening requires continuous monitoring to adherence repeat screening in high risk adults to achieve similar results. Repeat annual screening is necessary for early detection of lung cancer. Baseline or first LDCT scans detect prevalent lung cancer, when subsequent screening detects new nodules. However, adherence to screening is low, ranging at 28-38% from centers nationally.

The investigators developed two novel, patient-centered interventions to address patient education and offering reminders for on-time screening. To address these goals, the specific aims are to: 1) Compare effectiveness of two multilevel interventions relative to usual care in improving (a) rates of adherence to lung cancer screening, (b) patient-centered outcomes; and (c) clinic outcomes; and 2) Determine the patient-, clinician-, and system-level factors that influence changes in adherence to inform lung cancer screening programs.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 1606
• Est. completion date: June 30, 2026
• Est. primary completion date: June 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 78 Years

Eligibility

Inclusion Criteria:

• KPWA members

• Aged 50-78 years

• Have a negative screening LDCT scan

• Speak English or Spanish

• Meet US Preventive Services Task Force guidelines

Exclusion Criteria:

• Patients who were previously diagnosed with lung cancer,

• Patients who have a positive scan,

• Patients who have an indicator for interpreter services, except for Spanish

Related Conditions & MeSH terms

• Lung Cancer
• Lung Cancer Screening
• Lung Neoplasms

Intervention

Other:
• Stepped Reminders
Stepped Reminders, which directly reminds providers to order the next LDCT scan and then reminds patients they are due and prompts them to schedule LDCT with Radiology.
• Patient Education
The Patient Voices Video is an educational video about lung cancer screening.

Locations

Country	Name	City	State
United States	Kaiser Permanente	Seattle	Washington

Sponsors (3)

Lead Sponsor	Collaborator
Kaiser Permanente	Fred Hutchinson Cancer Center, Hackensack Meridian Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of repeat annual lung cancer screening	Electronic health records will be searched for screening low dose CT (LDCT).	9-15 months after index LDCT
Secondary	Knowledge of lung cancer screening	Knowledge of lung cancer screening eligibility, time to return and cost on patient reported outcomes survey.	8 weeks after index LDCT
Secondary	Attitudes and beliefs	The Lung Cancer Screening Health Belief Scales: 1) perceived risk of lung cancer (3 items); 2) perceived benefits of lung cancer screening (6 items); (3) perceived barriers to lung cancer screening (17 items); and (4) self-efficacy for lung cancer screening (9 items).	8 weeks after index LDCT